Based on our findings of activation of OXPHOS and mTOR signaling along with decreased α-KG levels in MPN patient platelets, we tested whether α-KG supplementation could revert platelet metabolic alterations in the context of MPN. This evidence concerns the gene MTOR and myeloproliferative disorder.